You know the healthcare system’s been bleeding out talent for years. Burnout, shortages, inefficiency, it’s like watching a cassette deck in a streaming world. But Cobionix? They’re not slapping a Band-Aid on the problem. They’re building the future, and this week, they just picked up another scalpel.
On July 9, Cobionix locked in $3 million in fresh strategic funding. Led by TitletownTech, yes, the same VC firm powered by Microsoft and the Green Bay Packers, this round also brought in Lions Investment, Dr. Paul McBeth (who happens to be one of Canada’s top minds in trauma surgery and robotics), and a lineup of returning believers from their $2.2M raise in 2023. You don’t double down unless the data, and the people, are too sharp to ignore.
Founded in 2021 by Dr. Tim Lasswell, Nima Zamani, and John Van Leeuwen, and now fronted by CEO Matthew Sefati, Cobionix isn’t just tinkering with automation, they’re deploying CODI®, a robotic platform that’s more adaptable than most startups’ pitch decks. Diagnostic ultrasound? Handled. Remote intramuscular injections? Already in the books. All autonomous. All real. And it’s already running pilots across Canada, the U.S., and the UK. Think NHS, Saskatchewan Health Authority, and Prevea Health, not exactly low-hanging fruit.
What makes CODI® hit different? Seven degrees of freedom, AI-powered control with real-time haptic feedback, and 5G integration for remote procedures. It’s not just a robot, it’s a fully loaded med-tech utility player that’s built to move from clinic to battlefield, from rural outposts to urban pressure zones. While others are prototyping, Cobionix is deploying. While others pitch potential, they’ve already delivered the world’s first autonomous intramuscular injection back in 2021. That’s not a claim. That’s a timestamp in history.
The path forward is textbook hustle with clinical edge: commercialize the platform, scale pilots, push through FDA and Health Canada, and bring precision medicine to places most systems forgot. U.S. market entry by mid-2026. Canada and UK scaling underway. And let’s be honest, if your tech works in rural Saskatchewan and the NHS bureaucracy, you’re not vaporware. You’re battle-tested.
Cobionix isn’t just a robotics company. It’s a healthcare defibrillator dressed like Iron Man with a med school GPA. And this $3M round? It’s the fuel to push CODI® from R&D to real-world transformation. Shoutout to Matthew Sefati, Nima Zamani, Dr. Tim Lasswell, and John Van Leeuwen, plus the investors who saw past the noise and into the signal. Healthcare doesn’t need another app. It needs intelligent machines that show up, don’t call in sick, and perform on cue.
That’s not automation. That’s evolution. Cobionix is already coding it.
